StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)

Latest, FY2024
677
Period ended Dec 31, 2024
Change on a year earlier
-7.1%
728 in FY2023
History
11 years
Since FY2014
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBasaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
FY2024Dec 31, 2024677-7.1%Form 10-K (filed 2025-02-19) ↗
FY2023Dec 31, 2023728-4.2%Form 10-K (filed 2025-02-19) ↗
FY2022Dec 31, 2022760-14.8%Form 10-K (filed 2025-02-19) ↗
FY2021Dec 31, 2021893-20.6%Form 10-K (filed 2024-02-21) ↗
FY2020Dec 31, 20201,124+1.1%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 20191,113+38.9%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 2018801+85.4%Form 10-K (filed 2021-02-17) ↗
FY2017Dec 31, 2017432+401.9%Form 10-K (filed 2020-02-19) ↗
FY2016Dec 31, 201686.1+675.7%Form 10-K (filed 2019-02-19) ↗
FY2015Dec 31, 201511.1–Form 10-K (filed 2017-02-21) ↗
FY2014Dec 31, 20140–Form 10-K (filed 2017-02-21) ↗

Breakdown

What makes up basaglar (insulin glargine) — worldwide revenue ($m) [legacy separate disclosure]

Cite this data

StockData. (2026). Eli Lilly Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure] ($M), annual FY2014–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_basaglar_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.